What GLP-1s Can and Can't Do — A Clinical Perspective

GLP-1 medications have become one of the most talked-about developments in metabolic medicine in recent years — and for good reason. The clinical evidence behind them is substantial, the results for the right patients are meaningful, and their ability to address the physiological drivers of weight resistance represents a genuine shift in how medicine approaches metabolic health.

They are also frequently misunderstood, overprescribed without clinical context, and positioned in the popular conversation as something they are not — a permanent solution that removes the need to address the underlying drivers of metabolic dysfunction.

This is a clinical perspective on what these medications actually do, who they are appropriate for, and what they cannot do on their own.

What GLP-1s actually are

GLP-1 agonists — including medications like semaglutide and tirzepatide — are a class of medications that mimic the action of glucagon-like peptide-1, a hormone naturally produced in the gut in response to food intake.

GLP-1 has several important functions. It stimulates insulin secretion in response to elevated blood glucose, suppresses glucagon release, slows gastric emptying, and acts on the brain to reduce appetite and increase satiety. GLP-1 agonists amplify and extend these effects — reducing hunger signaling, slowing the rate at which the stomach empties, and improving the cellular response to insulin.

The result, in the right clinical context, is meaningful reduction in appetite, improved blood sugar regulation, and significant weight loss in many patients.

What they do well

For patients with insulin resistance, metabolic syndrome, type 2 diabetes, or significant weight to lose, GLP-1 medications can be genuinely transformative. They address the physiological underpinnings of hunger and satiety dysregulation in a way that willpower and caloric restriction alone cannot. They improve glycemic control. They reduce cardiovascular risk in specific populations. And they can break the cycle of metabolic resistance that prevents weight loss despite consistent effort.

For women in perimenopause whose metabolic changes have created conditions that don't respond to the approaches that worked earlier in life, GLP-1 support — when clinically appropriate and properly managed — can be a meaningful component of a broader metabolic protocol.

What they can't do

This is the part of the conversation that is most frequently missing.

GLP-1 medications reduce appetite. They do not improve the nutritional quality of what you eat when you do eat. A patient eating significantly less but still eating in patterns that drive inflammation and blood sugar dysregulation will achieve weight loss but not metabolic health. These are not the same thing.

GLP-1 medications support weight loss — but a significant portion of the weight lost without adequate protein intake and resistance training is lean muscle mass, not fat. Losing muscle in the process of losing weight slows resting metabolic rate, worsens body composition, and creates the conditions for rapid weight regain when the medication is discontinued.

GLP-1 medications do not address the hormonal, gut, or stress physiology patterns that may be contributing to metabolic dysfunction. They work on one mechanism — appetite and insulin signaling — while leaving others unaddressed.

And critically — GLP-1 medications prescribed without a comprehensive clinical evaluation and ongoing support are not being used to their potential. Knowing that a patient has insulin resistance, thyroid dysfunction, elevated inflammatory markers, or significant nutritional deficiencies changes how a GLP-1 protocol should be structured and monitored.

The right way to use them

GLP-1 support is most effective when it is one component of a comprehensive metabolic protocol — not the whole protocol. That means:

A thorough clinical evaluation before prescribing — understanding the full metabolic, hormonal, and inflammatory picture rather than prescribing based on weight alone.

Nutritional guidance that prioritizes protein adequacy and anti-inflammatory eating patterns to protect lean mass and support the body during weight loss.

Resistance training as a non-negotiable component to preserve and build the muscle that supports long-term metabolic health.

Regular monitoring — not just of weight, but of body composition, metabolic markers, and how the patient is feeling throughout the process.

A plan for what comes after — because the goal is not permanent medication dependence. It is metabolic stability that can be maintained with the lifestyle and hormonal foundations that were built alongside the medication.

GLP-1s are a powerful tool. Like all tools, their value depends entirely on how they're used.

The Metabolic Protocol at Energē Health includes GLP-1 support when clinically appropriate — as part of a comprehensive, supervised program built around your complete metabolic picture.